Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Meeting Home > Live Events > Session Recording
Short Talks > Session
Short Talks - Emerging Therapeutics and Prophylactic Strategies in Coagulation Disorder
Moderators
Rushad Patell, Gabe Fontaine
Information
Not available for CE.


No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.
Presentations
10:30 THE EFFECT OF FIBRINOGEN CONCENTRATE ON CLOT STRENGTH IN PATIENTS WITH CONGENITAL AND ACQUIRED FIBRINOGEN DEFICIENCY
Suchitra Acharya1, Trupti Mehta Shah2, Cristina Solomon3, Sigurd Knaub3, Claudia Djambas Khayat4, Ashok Roy5, Faheez Mohamed5, Keyvan Karkouti6, Jeannie Callum7,8, Toshko Lissitchkov9, Flora Peyvandi10,11. 1Northwell Health, New Hyde Park, NY, USA 2Octapharma USA, Paramus, NJ, USA 3Octapharma AG, Lachen, Switzerland 4Hospital Hôtel Dieu de France, Saint Joseph University, Beirut, Lebanon 5Peritoneal Malignancy Institute, Basingstoke, United Kingdom 6University of Toronto, Toronto, ON, Canada 7Queen’s University, Kingston, ON, Canada 8Kingston Health Sciences Centre, Kingston, ON, Canada 9Specialized Hospital for Active Treatment (SHAT) “Joan Pavel”, Sofia, Bulgaria 10Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy 11Università degli Studi di Milano, Milan, Italy
10:42 SUBCUTANEOUS FOUR-WEEK DOSING OF THE NOVEL PROTEIN S ANTIBODY VGA039 DEMONSTRATES SAFETY AND CLINICALLY MEANINGFUL BLEED REDUCTION IN PATIENTS WITH VON WILLEBRAND DISEASE: PHASE 1/2 MULTI-DOSE STUDY RESULTS
Nicoletta C. Machin1, Shrinath Kshirsagar2, Adam Giermasz3, Johnny Mahlangu4, Gabriela Yamaguti-Hayakawa5, Savita Rangarajan6, Genevieve Moyer7, Christine Kempton8, Jane Mason9, Michelle Sholzberg10, Paula Villaça11, Sandip Panicker12, Eileen K. Sawyer12, Gary Patou12, Benjamin Kim12, Allison P. Wheeler13. 1Division of Classical Hematology, Department of Medicine, University of Pittsburgh and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA 2Advanced Center for Oncology, Haematology & Rare Disorders, K. J. Somaiya Medical College & Research Center, Somaiya Ayurvihar, Mumbai, India 3Division of Hematology/Oncology, Department of Medicine, University of California Davis, Sacramento, CA, USA 4Haemophilia Comprehensive Care Centre, Charlotte Maxeke Johannesburg Hospital, University of the Witwatersrand, Johannesburg, South Africa 5Hemocentro UNICAMP, University of Campinas, Campinas, Brazil 6University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom 7The University of Colorado Hemophilia and Thrombosis Center, Aurora, CO, USA 8Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA 9Queensland Haemophilia Centre, Department of Haematology and BMT, Royal Brisbane and Women’s Hospital, Brisbane, Australia 10Departments of Medicine, and Laboratory Medicine and Pathobiology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada 11Hospital das Clínicas,University of São Paulo, São Paulo, Brazil 12Star Therapeutics, Inc., South San Francisco, CA, USA 13Washington Center for Bleeding Disorders and Divisions of Pediatric Hematology/Oncology and Hematology/Oncology, University of Washington, Seattle, WA, USA
10:54 NXT007 PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITH OR WITHOUT FVIII INHIBITORS: A GLOBAL PHASE I/II MULTIPLE-ASCENDING-DOSE STUDY
Maria Elisa Mancuso1, 2, Davide Matino3, Dan Hart4, Francisco José López-Jaime5, Christophe Schmitt6, Sanjay Ahuja7, Giuliana Ventriglia6, Anna Kiialainen6, Laura Young8, Olivier Catalani6, Mark Belletrutti9, Tom Chu 10, Jerzy Windyga11, Víctor Jiménez-Yuste12, Michaela Lehle6, Janice M. Staber13. 1Humanitas University, Pieve Emanuele, Milan, Italy 2Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy 3McMaster University, Hamilton, Ontario, Canada 4Roche Products Ltd, Welwyn Garden City, United Kingdom 5Hospital Universitario Regional de Málaga, Málaga, Spain 6F. Hoffmann-La Roche Ltd, Basel, Switzerland 7Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA 8Auckland City Hospital, Auckland, New Zealand 9Department of Pediatrics, University of British Colombia, Vancouver, British Columbia, Canada 10Genentech, Inc., South San Francisco, CA, USA 11Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland 12La Paz University Hospital-IdiPAZ, Autónoma University, Madrid, Spain 13Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
11:06 EXPLORATORY ANALYSIS OF INTRINSIC PATHWAY-TRIGGERED THROMBIN GENERATION INHIBITION IN HEALTHY VOLUNTEERS AND PATIENTS POST-TOTAL KNEE ARTHROPLASTY WHO RECEIVED REGN9933A2 AND REGN7508CAT
Karoline A. Meagher, Kusha Mohammadi, Dateng Li, Ethan Marin, Aaron Kithcart, Meagan P. O’Brien, Selin Somersan-Karakaya, KehDih Lai, Dan Chalothorn, Robert J. Durso, Michael E. Burczynski, Poulabi Banerjee, David E. Gutstein. Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
11:18 FIRST-IN-HUMAN INVESTIGATION OF HMB-002: A SUBCUTANEOUS ANTIBODY FOR PROPHYLACTIC MANAGEMENT OF VON WILLEBRAND DISEASE
Priyanka Raheja1, Amy Knott2, Ulrike Lorch3, Henrik Ostergaard4, Catherine Rea4. 1Department of Hematology, The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom 2Bristol Haematology Unit, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom 3Richmond Pharmacology, London, United Kingdom 4Hemab Therapeutics, Cambridge, MA, USA